Your browser doesn't support javascript.

BVS del Sindicato Médico del Uruguay

Portal de Búsqueda de la BVS

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.

Wei, Mei; Maurer, Kathryn A; Henry, N Lynn.
Breast J ; 25(6): 1254-1256, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31273878
Ovarian remnant syndrome (ORS), in which a portion of the ovary is retained following bilateral salpingo-oophorectomy (BSO), is uncommon but can negatively impact patient management. Evaluation should be performed in a patient who has clinical signs or symptoms suggestive of ORS, especially in a premenopausal woman with breast cancer who is treated with an aromatase inhibitor following bilateral salpingo-oophorectomy (BSO), or a woman with a pathogenic variant in BRCA1 or BRCA2 who undergoes BSO for ovarian cancer risk reduction.